WuXi AppTec News More News
WuXi AppTec Historical Prices
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:
0%
0
WuXi AppTec Analyst Opinions
- All
- Buy
- Hold
- Sell
WuXi AppTec Estimates* in CNY
| 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|
| Revenue | 45,452 | 58,147 | 68,415 | - |
| Dividend | 0.68 | 0.87 | - | - |
| Dividend Yield (in %) | 0.86 % | 1.10 % | - | - |
| EPS | 3.30 | 4.21 | - | - |
| P/E Ratio | 23.08 | 18.10 | - | - |
| EBIT | 11,027 | 14,188 | 15,564 | 23,552 |
| EBITDA | 13,118 | 16,599 | - | - |
| Net Profit | 9,812 | 12,503 | 13,304 | - |
| Net Profit Adjusted | 9,687 | 12,392 | - | - |
| Pre-Tax Profit | 11,467 | 14,718 | 15,746 | - |
| Net Profit (Adjusted) | 11,212 | 14,205 | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - |
| EPS (GAAP) | 3.22 | 4.09 | - | - |
| Gross Income | 17,186 | 22,396 | 24,835 | - |
| Cash Flow from Investing | -5,836 | -5,477 | - | - |
| Cash Flow from Operations | 10,957 | 12,213 | - | - |
| Cash Flow from Financing | -1,988 | -2,681 | - | - |
| Cash Flow per Share | 3.54 | 3.92 | - | - |
| Free Cash Flow | 3,007 | 6,165 | 7,162 | 12,831 |
| Free Cash Flow per Share | 1.50 | 2.00 | - | - |
| Book Value per Share | 18.52 | 21.84 | - | - |
| Net Debt | -4,914 | -7,657 | - | - |
| Research & Development Exp. | 1,768 | 2,320 | 2,395 | - |
| Capital Expenditure | 6,587 | 6,293 | 9,914 | 8,642 |
| Selling, General & Admin. Exp. | 5,751 | 7,215 | - | - |
| Shareholder’s Equity | 55,855 | 66,361 | - | - |
| Total Assets | 77,662 | 92,510 | - | - |
|
Previous Quarter ending 12/31/22 |
Current Quarter | Next Quarter |
Current Year ending 12/31/23 |
Next Year ending 12/31/24 |
|
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 3 | 1 | 1 | 32 | 32 |
| Average Estimate | 0.578 CNY | 0.570 CNY | 0.610 CNY | 3.304 CNY | 4.214 CNY |
| Year Ago | - | 0.530 CNY | - | - | 3.304 CNY |
| Publish Date | 3/20/2023 | 5/2/2023 | 8/22/2023 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 3 | - | - | 30 | 30 |
| Average Estimate | 11,029 CNY | - | - | 45,452 CNY | 58,147 CNY |
| Year Ago | - | - | - | - | 45,452 CNY |
| Publish Date | 3/20/2023 | - | - | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
WuXi AppTec Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2021 | WuXi AppTec Co., Ltd. Registered Shs -A- | 0.51 | 0.43 | CNY |
| 2020 | WuXi AppTec Co., Ltd. Registered Shs -A- | 0.32 | 0.28 | CNY |
| 2019 | WuXi AppTec Co., Ltd. Registered Shs -A- | 0.19 | 0.35 | CNY |
| 2018 | WuXi AppTec Co., Ltd. Registered Shs -A- | 0.24 | 0.74 | CNY |
| 2017 | WuXi AppTec Co., Ltd. Registered Shs -A- | - | - | CNY |
| 2016 | WuXi AppTec Co., Ltd. Registered Shs -A- | - | - | CNY |
| 2015 | WuXi AppTec Co., Ltd. Registered Shs -A- | - | - | CNY |
*Yield of the Respective Date
WuXi AppTec Co., Ltd. Registered Shs -A- Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | 0.578 CNY | Q4 2022 Earnings Release | 03/20/2023 |
| Earnings Report | 0.570 CNY | Q1 2023 Earnings Release | 05/02/2023 |
| Earnings Report | 0.610 CNY | Q2 2023 Earnings Release | 08/22/2023 |
| Earnings Report | - | Q3 2023 Earnings Release | 11/02/2023 |
| Earnings Report | - | Q4 2023 Earnings Release | 03/20/2024 |
WuXi AppTec Profile
WuXi AppTec Co., Ltd. provides an integrated pharmaceutical platform for the research, development, and production of new drugs. It operates through the following business segments: Contract research organization (CRO) services, Contract manufacturing organization (CMO)/Contract development and manufacturing organization (CDMO) business, and Others. The CRO services segment includes laboratory services in China, laboratory services in the United States, and clinical research services. The company was founded by Ge Li, Ning Zhao, Xiao Zhong Liu, Zhao Hui Zhang, and Tao Lin on December 1, 2000 and is headquartered in Shanghai, China.
Moody’s Daily Credit Risk Score
WuXi AppTec Shareholder
| Owner | in % |
|---|---|
| Freefloat | 61.18 |
| Ge Li, PhD | 25.47 |
| Pavilion Capital Pte Ltd | 6.22 |
| Shanghai Zhongmin Yinfu Capital Management Co. Ltd. | 4.54 |
| New Wuxi Life Science Holdings Ltd. | 3.27 |
| Zhong Ou Medical Health Hybrid Fund | 2.39 |
| Boyu Capital Advisory Co. Ltd. | 1.87 |
| Hillhouse Investment Management Ltd. (Invest) | 1.70 |
| Hai Shan Zhou | 1.51 |
| Invesco Great Wall Emerging Growth Fund | 1.17 |
| Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt) | 1.17 |
| Yue Chen | 0.86 |
| American Funds EuroPacific Growth Fund | 0.72 |
| ICBCCS Qianyan Medical Equity Fund | 0.62 |
| UBS Asset Management Switzerland AG | 0.60 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.